On March 2, 2022, Jeffrey K. Tong, Ph.D., notified the board of directors of Nurix Therapeutics, Inc. that he will resign as a Class II member of the Board and as a member of the Board's Audit Committee and Compensation Committee, effective on the date of the Company's 2022 Annual Meeting of Stockholders (the Resignation"). The Resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.68 USD | -3.98% | -0.44% | +51.94% |
05-28 | Nurix Therapeutics, Inc. Appoints Paula G. O?Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer | CI |
05-20 | Nurix Therapeutics Names New Board Chair | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.94% | 930M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.53% | 22.78B | |
-10.90% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- NRIX Stock
- News Nurix Therapeutics, Inc.
- Nurix Therapeutics, Inc. Announces Resignation of Jeffrey K. Tong as Class II Member of the Board and as a Member of the Board's Audit Committee and Compensation Committee